ArticleEBioMedicine2020
Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes.
Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.Cancer discovery · 2022Trial
- A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers.Breast cancer research : BCR · 2026Article
- Blood biomarkers of response to concomitant intratympanic and systemic corticosteroids treatment for idiopathic sudden sensorineural hearing loss.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis.Breast cancer research and treatment · 2025Article
- Ligand discrimination in immune cells: Signal processing insights into immune dysfunction in ER+ breast cancer.PLoS computational biology · 2025Article
- Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphoma.Scientific reports · 2025Article
- CCR4-NOT Transcription Complex Subunit 7 (CNOT7) Protein and Leukocyte-Associated Immunoglobulin-like Receptor-1 in Breast Cancer Progression: Clinical Mechanistic Insights and In Silico Therapeutic Potential.International journal of molecular sciences · 2025Article
- Epigenomic preconditioning of peripheral monocytes determines their transcriptional response to the tumor microenvironment.Genome medicine · 2025Article
- Single-cell transcriptomic profiling of immune landscape in triple-negative breast cancer during neoadjuvant chemotherapy.NPJ systems biology and applications · 2025Article
- Fasting and fasting-mimicking conditions in the cancer immunotherapy era.Journal of physiology and biochemistry · 2025Review
- Development of a risk prediction nomogram model of pyrotinib-induced severe diarrhea.BMC cancer · 2025Article
- Single-cell analysis reveals potential therapeutic markers of peripheral blood mononuclear cells from bladder cancer patients.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Heterogeneity of monocytes in cancer.American journal of cancer research · 2025Review
- Sleep disorders in cancer: interactions and intrinsic links.Frontiers in oncology · 2025Review
- Decreased IL-10R-expressing B Cells in breast cancer patients: a potential biomarker for early cancer detection.American journal of clinical and experimental immunology · 2025Article
- Article
- Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients' blood.NPJ systems biology and applications · 2024Article
- Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours.Clinical and translational medicine · 2024Review
- The Role of Salivary Vascular Endothelial Growth Factor A, Cytokines, and Amino Acids in Immunomodulation and Angiogenesis in Breast Cancer.Biomedicines · 2024Article
- Atypical memory B cells increase in the peripheral blood of patients with breast cancer regardless of lymph node involvement.BMC immunology · 2024Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
backgroundIt is increasingly recognized that cancer progression induces systemic immune changes in the host. Alterations in number and function of immune cells have been identified in cancer patients' peripheral blood and lymphoid organs. Recently, we found dysregulated cytokine signaling in peripheral blood T cells from breast cancer (BC) patients, even those with localized disease.
methodsWe used phosphoflow cytometry to determine the clinical significance of cytokine signaling responsiveness in peripheral blood monocytes from non-metastatic BC patients at diagnosis. We also examined the correlation between cytokine signaling in peripheral monocytes and the number of tumor-infiltrating macrophages in paired breast tumors.
findingsOur results show that cytokine (IFNγ) signaling may also be dysregulated in peripheral blood monocytes at diagnosis, specifically in BC patients who later relapsed. Some patients exhibited concurrent cytokine signaling defects in monocytes and lymphocytes at diagnosis, which predict the risk of future relapse in two independent cohorts of BC patients. Moreover, IFNγ signaling negatively correlates with expression of CSF1R on monocytes, thus modulating their ability to infiltrate into tumors.
interpretationOur results demonstrate that tumor-induced systemic immune changes are evident in peripheral blood immune cells for both myeloid and lymphoid lineages, and point to cytokine signaling responsiveness as important biomarkers to evaluate the overall immune status of BC patients.
fundingThis study was supported by the Department of Defense Breast Cancer Research Program (BCRP), The V Foundation, Stand Up to Cancer (SU2C), and Breast Cancer Research Foundation (BCRF).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.